| Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
Odds ratio | 95% CI | p value | Odds ratio | 95% CI | p value | |
Age | 1.02 | 0.885–1.18 | 0.751 |  |  |  |
Gender (male/female) | 1.18 | 0.197–7.08 | 0.855 |  |  |  |
Never smoker (%) | 0.857 | 0.104–7.04 | 0.886 |  |  |  |
Body weight (kg) | 0.931 | 0.861–1.01 | 0.0702 |  |  |  |
Body mass index | 0.704 | 0.519–0.955 | 0.0239 | 0.487 | 0.280–0.849 | 0.0111 |
Body surface area (DuBois, m2) | 0.0418 | 0.000541–3.22 | 0.152 |  |  |  |
Creatinine (mg/dL) | 1.07 | 0.0280–40.7 | 0.972 |  |  |  |
Krebs von den Lungen-6 (U/mL) | 1 | 0.999–1.00 | 0.348 |  |  |  |
Surfactant protein D (ng/dL) | 0.995 | 0.989–1.00 | 0.08 | 0.997 | 0.990–1.00 | 0.315 |
Forced vital capacity (L) | 0.561 | 0.150–2.1 | 0.391 |  |  |  |
% Forced vital capacity (%) | 0.967 | 0.918–1.02 | 0.213 |  |  |  |
% DLco (%) | 1.01 | 0.9580–1.06 | 0.739 |  |  |  |
Administration period of Pirfenidone | 1 | 0.999–1.00 | 0.329 |  |  |  |
Time from pirfenidone discontinuation to nintedanib initiation | 1.01 | 0.994–1.02 | 0.355 |  |  |  |
Discontinued pirfenidone due to FVC decline | 0.333 | 0.0751–1.48 | 0.148 |  |  |  |
Anorexia during the period of pirfenidone | 1.65 | 0.370–7.37 | 0.512 |  |  |  |
Weight loss during the period of pirfenidone | 2.93 | 0.657–13.1 | 0.159 |  |  |  |
Weight loss with grade ≥ 2 during the period of pirfenidone | 7.8 | 0.804–75.6 | 0.0764 | 3.29 | 0.184–58.8 | 0.418 |